Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 1
1989 7
1990 3
1991 3
1992 6
1993 6
1994 4
1995 3
1996 8
1997 4
1998 3
1999 3
2000 4
2001 4
2002 2
2003 3
2005 2
2006 5
2007 2
2008 2
2009 1
2010 3
2011 5
2012 1
2013 2
2014 2
2021 2
2022 4
2023 2
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Clinical pharmacokinetics of ramipril.
Meisel S, Shamiss A, Rosenthal T. Meisel S, et al. Clin Pharmacokinet. 1994 Jan;26(1):7-15. doi: 10.2165/00003088-199426010-00002. Clin Pharmacokinet. 1994. PMID: 8137599 Review.
After absorption from the gastrointestinal tract, rapid hydrolysis of ramipril occurs in the liver. In the therapeutic concentration range, protein binding of ramipril and ramiprilat is 73 and 56%, respectively. Ramiprilat binds to ACE with high affinity at c …
After absorption from the gastrointestinal tract, rapid hydrolysis of ramipril occurs in the liver. In the therapeutic concentration …
The analysis of ramipril/ramiprilat concentration in human serum with liquid chromatography-tandem mass spectrometry - interpretation of high concentrations for the purposes of forensic toxicology.
Dziadosz M, Rosenberger W, Klintschar M, Teske J. Dziadosz M, et al. Forensic Sci Med Pathol. 2024 Mar;20(1):100-105. doi: 10.1007/s12024-023-00621-6. Epub 2023 Apr 15. Forensic Sci Med Pathol. 2024. PMID: 37060536 Free PMC article.
Ramipril is a popular angiotensin-converting enzyme inhibitor applied in the treatment of hypertension. Its therapeutic effect is oriented on the concentration of the active metabolite ramiprilat. ...Most real samples targeted for ramipril/ramiprilat were ass …
Ramipril is a popular angiotensin-converting enzyme inhibitor applied in the treatment of hypertension. Its therapeutic effect is ori …
Expressional profile of cardiac uncoupling protein-2 following myocardial ischemia reperfusion in losartan- and ramiprilat-treated rats.
Safari F, Bayat G, Shekarforoush S, Hekmatimoghaddam S, Anvari Z, Moghadam MF, Hajizadeh S. Safari F, et al. J Renin Angiotensin Aldosterone Syst. 2014 Sep;15(3):209-17. doi: 10.1177/1470320312474050. Epub 2013 Jan 31. J Renin Angiotensin Aldosterone Syst. 2014. PMID: 23372044 Free article.
BACKGROUND AND AIMS: The aim of this study was to investigate the early changes of cardiac uncoupling protein-2 (UCP2) expression following myocardial ischemia reperfusion in rats chronically treated with ramiprilat and losartan. METHODS: Male Wistar rats were assigned int …
BACKGROUND AND AIMS: The aim of this study was to investigate the early changes of cardiac uncoupling protein-2 (UCP2) expression following …
Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Lefebvre HP, Jeunesse E, Laroute V, Toutain PL. Lefebvre HP, et al. J Vet Intern Med. 2006 May-Jun;20(3):499-507. doi: 10.1892/0891-6640(2006)20[499:pappor]2.0.co;2. J Vet Intern Med. 2006. PMID: 16734081 Free article. Clinical Trial.
Ramipril, an angiotensin-converting enzyme (ACE) inhibitor for use in dogs, is converted in vivo to its active form, ramiprilat, which is eliminated in the bile and urine in the dog. The objective of this study was to assess the effect of renal impairment on the pharmacoki …
Ramipril, an angiotensin-converting enzyme (ACE) inhibitor for use in dogs, is converted in vivo to its active form, ramiprilat, whic …
Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.
Levitt DG, Schoemaker RC. Levitt DG, et al. BMC Clin Pharmacol. 2006 Jan 6;6:1. doi: 10.1186/1472-6904-6-1. BMC Clin Pharmacol. 2006. PMID: 16398929 Free PMC article.
The model includes: 1) two independent ACE binding sites; 2) non-equilibrium time dependent binding; 3) liver and kidney ramipril intracellular uptake, conversion to ramiprilat and extrusion from the cell; 4) intestinal ramipril absorption. The experimental in vitro ram …
The model includes: 1) two independent ACE binding sites; 2) non-equilibrium time dependent binding; 3) liver and kidney ramipril intracellu …
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.
Safari F, Hajizadeh S, Shekarforoush S, Bayat G, Foadoddini M, Khoshbaten A. Safari F, et al. J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):29-35. doi: 10.1177/1470320311426025. Epub 2011 Nov 10. J Renin Angiotensin Aldosterone Syst. 2012. PMID: 22076778 Free article.
HYPOTHESIS/INTRODUCTION: Our aim was to investigate whether a non-hypotensive dose of ramiprilat and losartan has myocardial protective effects during myocardial ischemia/reperfusion in vivo. ...There were no significant decreases in episodes of VT, the incidence of irreve …
HYPOTHESIS/INTRODUCTION: Our aim was to investigate whether a non-hypotensive dose of ramiprilat and losartan has myocardial protecti …
High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers.
Lu XY, Shen-Tu JZ, Liu J. Lu XY, et al. J Pharm Biomed Anal. 2006 Feb 13;40(2):478-83. doi: 10.1016/j.jpba.2005.07.054. Epub 2005 Sep 21. J Pharm Biomed Anal. 2006. PMID: 16181761 Clinical Trial.
The assay linearities of ramipril and ramiprilat were confirmed over the range 0.10-100 ngml(-1) and 0.25-100 ngml(-1), respectively, and limits of quantitation for them were 0.10 and 0.25 ngml(-1), respectively. ...Intraday and interday relative standard deviations of ram …
The assay linearities of ramipril and ramiprilat were confirmed over the range 0.10-100 ngml(-1) and 0.25-100 ngml(-1), respectively, …
Population pharmacokinetics of ramipril in patients with chronic heart failure: A real-world longitudinal study.
Trobec KČ, Grabnar I, Trontelj J, Lainščak M, Kos MK. Trobec KČ, et al. Acta Pharm. 2024 May 30;74(2):315-328. doi: 10.2478/acph-2024-0018. Print 2024 Jun 1. Acta Pharm. 2024. PMID: 38815200 Free article.
Pharmacokinetics were assessed using a nonlinear mixed-effects parent-metabolite model comprising two compartments for ramipril and one compartment for ramiprilat. The influence of body size and composition was best described by an allometric relationship with fat-free mas …
Pharmacokinetics were assessed using a nonlinear mixed-effects parent-metabolite model comprising two compartments for ramipril and one comp …
Aliskiren versus ramipril in hypertension.
Verdecchia P, Angeli F, Mazzotta G, Martire P, Garofoli M, Gentile G, Reboldi G. Verdecchia P, et al. Ther Adv Cardiovasc Dis. 2010 Jun;4(3):193-200. doi: 10.1177/1753944710369682. Epub 2010 Apr 23. Ther Adv Cardiovasc Dis. 2010. PMID: 20418269 Free article. Review.
Another potential explanation may be the longer terminal elimination halflife of aliskiren (about 40 hours) compared with ramiprilat (13-17 hours). These data provide further evidence that aliskiren monotherapy provides a sustained BP reduction over the 24 hours....
Another potential explanation may be the longer terminal elimination halflife of aliskiren (about 40 hours) compared with ramiprilat …
Direct effects of the angiotensin-converting enzyme inhibitor ramiprilat on adult rat ventricular cardiomyocytes.
Helmig S, Schuckenböhmer P, Heger J, Euler G, Piper HM, Schlüter KD. Helmig S, et al. Acta Physiol (Oxf). 2007 Dec;191(4):267-74. doi: 10.1111/j.1748-1716.2007.01738.x. Epub 2007 Sep 7. Acta Physiol (Oxf). 2007. PMID: 17825088
In cardiomyocytes, bradykinin but not ramiprilat activated AP-1. Ramiprilat activates AP-1 in endothelial cells that are known to respond to ramiprilat in this way. ...This newly described effect of ramiprilat may contribute to the protective effects s …
In cardiomyocytes, bradykinin but not ramiprilat activated AP-1. Ramiprilat activates AP-1 in endothelial cells that are known …
93 results